Clinical Trial Update: CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating CH14.18 1021 antibody and IL-2 after haploidentical stem cell transplant in children with relapsed neuroblastoma has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• CH14.18 1021 antibody
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: University Children's Hospital Tuebingen | Conditions: Neuroblastoma Recurrent | Phase 2 | Status: COMPLETED